APA (7th ed.) Citation

Philippou, Y., Protheroe, A., & Bryant, R. (2020). Re: Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. Elsevier.

Chicago Style (17th ed.) Citation

Philippou, Y., AS Protheroe, and RJ Bryant. Re: Pembrolizumab for Treatment-refractory Metastatic Castration-resistant Prostate Cancer: Multicohort, Open-label Phase II KEYNOTE-199 Study. Elsevier, 2020.

MLA (9th ed.) Citation

Philippou, Y., et al. Re: Pembrolizumab for Treatment-refractory Metastatic Castration-resistant Prostate Cancer: Multicohort, Open-label Phase II KEYNOTE-199 Study. Elsevier, 2020.

Warning: These citations may not always be 100% accurate.